Testing effectiveness (Phase 2)Study completedNCT03711578
What this trial is testing
Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)
Who this might be right for
Non Hodgkin Lymphoma
Rhizen Pharmaceuticals SA 20